Biological Study of Ampicillin Conjugated Silver Nanoparticles Against Staphylococcus Aureus (in Vitro Experiment)

Abstract

The current work aimed to study the effects of ampicillin conjugated silver nanoparticles against S. aureus. S. aureus were collected and selected from 70 patients (strains were found in samples in the 17(24.3%)) with urinary tract infection who were admittable in Azadi Teaching Hospital, Kirkuk city during a period from September 2021 to January 2022. In vitro activity, Ampicillin conjugated silver nanoparticles against highly multi resistance strains were evaluated by inhibition zone testing method. The results demonstrated that the UV spectrum showed maximum absorption (λ max) at 422 nm. Samples were collected from patients' wounds and as shown in Table (1). A total of 150 samples were taken from UTI patients, with an average of 91 (60.7%) samples for males and 59 (39.3%) for females. The results found that the isolated samples showed positive bacterial growth that was grown on optimal culture media such as blood agar by 68(45.3%), while the percentage of negative growth was 82(54.7%). The susceptibility test for staphylococcus aureus showed a different inhibition zone where the diameter of the inhibition for Aztreonam was 11.3 mm, while the diameter of the inhibition for Tobramycin was 15.8 mm. As for Trimethoprim and Ampicillin only, the inhibition zone diameter was 4.2 and 3.1 mm, respectively. On the other hand, inhibition zone diameter after using ampicillin conjugated silver nanoparticles, reached 42.7 mm. Therefore, it is concluded from the current study that ampicillin conjugated silver has antibacterial effects against staphylococcus aureus.